Tesamorelin vs Sermorelin: The Stabilised GHRH Analogue Against the Classic Fragment

Tesamorelin and sermorelin are both GHRH analogues — they work the same upstream lever, telling the pituitary to release its own growth hormone. The difference is durability and focus: sermorelin is the short, physiologic GHRH 1-29 fragment, while tesamorelin is a stabilised, more potent molecule with dedicated visceral-fat research behind it. Both are supplied by New-U for laboratory research only.

Same lever, different build

Sermorelin is the first 29 amino acids of GHRH — enough to activate the receptor, but it clears in minutes. Tesamorelin is a full-length GHRH(1-44) analogue with a trans-3-hexenoyl group that shields it from enzymatic breakdown, giving a stronger, longer GHRH signal. Both preserve the pituitary's somatostatin feedback, so GH stays within physiologic bounds.

Side-by-side

Sermorelin Tesamorelin Class GHRH 1-29 fragment Stabilised GHRH(1-44) analogue Receptor GHRH receptor GHRH receptor Stability / potency Short half-life, lower potency Protease-resistant, more potent & sustained Signature research area Natural GH-pulse restoration, sleep, recovery Visceral adipose tissue reduction; IGF-1 Regulatory status Formerly approved (Geref); now research compound FDA-approved as Egrifta (HIV lipodystrophy) Feedback preserved? Yes Yes Typical framing Gentle, physiologic GHRH probe Stronger, targeted GHRH probe

The visceral-fat distinction

The clearest reason to pick one over the other in research is the visceral-fat literature: tesamorelin is the GHRH analogue with dedicated data (and an FDA approval as Egrifta) for reducing visceral adipose tissue. Sermorelin raises GH more broadly but doesn't carry that targeted body-composition evidence. If the study endpoint is visceral fat or IGF-1 magnitude, tesamorelin is the molecule with the track record; if it's modelling a natural, gentle GH rhythm, sermorelin is the lighter-touch tool.

What about stacking?

Because both hit the same GHRH receptor, combining them is redundant. The productive pairing is a GHRH analogue plus a ghrelin-receptor agonist — see Ipamorelin vs Sermorelin for why two different receptors give supra-additive GH release.

Frequently Asked Questions

What is the difference between tesamorelin and sermorelin? Both are GHRH-receptor analogues. Sermorelin is the short GHRH 1-29 fragment with a brief half-life; tesamorelin is a stabilised full-length GHRH(1-44) analogue that resists breakdown, is more potent, and is the one studied (and approved as Egrifta) for visceral-fat reduction. Both research use only.

Is tesamorelin stronger than sermorelin? In research terms generally yes — its stabilising modification gives a more sustained GHRH signal and larger IGF-1/GH effects. Sermorelin's edge is closely mimicking the body's own physiologic pulse.

Which is better for fat-loss research? Tesamorelin has the dedicated visceral-fat data and approval; sermorelin raises GH more broadly without that targeted evidence. Research context only — not a weight-loss or human-use recommendation.

Can tesamorelin and sermorelin be combined? They share the GHRH receptor, so combining them is redundant. Researchers instead pair a GHRH analogue with a ghrelin-receptor agonist like ipamorelin to engage two pathways. Research model only.

Buy Tesamorelin from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

Part of the Growth hormone secretagogue research research area — explore related compounds, guides and sources.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research